Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last CNY31.95 CNY
Change Today +1.40 / 4.58%
Volume 14.7M
300267 On Other Exchanges
Symbol
Exchange
Shenzhen
As of 3:00 AM 05/22/15 All times are local (Market data is delayed by at least 15 minutes).

hunan er-kang pharmaceuti -a (300267) Snapshot

Open
CNY31.49
Previous Close
CNY30.55
Day High
CNY32.99
Day Low
CNY30.55
52 Week High
05/22/15 - CNY32.99
52 Week Low
06/19/14 - CNY14.08
Market Cap
29.0B
Average Volume 10 Days
12.5M
EPS TTM
CNY0.32
Shares Outstanding
909.0M
EX-Date
04/8/15
P/E TM
101.4x
Dividend
CNY0.05
Dividend Yield
0.16%
Current Stock Chart for HUNAN ER-KANG PHARMACEUTI -A (300267)

Related News

No related news articles were found.

hunan er-kang pharmaceuti -a (300267) Related Businessweek News

No Related Businessweek News Found

hunan er-kang pharmaceuti -a (300267) Details

Hunan Er-Kang Pharmaceutical Co., Ltd. is engaged in the research, development, production, and sale of pharmaceutical excipients and antibiotics primarily in China. The company produces various kinds of pharmaceutical excipients for tablets, injections, capsules, granule, pills, and oral liquids. Its principal pharmaceutical excipients include glycerol, medicinal alcohol, propylene glycol, medicinal sodium hydroxide, medicinal sucrose, etc. The company also provides APIs, such as glycerol, dilute hydrochloric acid, dihydroxypropyl theophylline, sulbenicillin sodium, and calamine powder. In addition, it offers various pharmaceutical preparations comprising sulbenicillin sodium injection and compound liquorice tablets. Hunan Er-Kang Pharmaceutical Co., Ltd. was founded in 2003 and is based in Changsha, China.

Founded in 2003

hunan er-kang pharmaceuti -a (300267) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

hunan er-kang pharmaceuti -a (300267) Key Developments

Hunan Er-Kang Pharmaceutical Co., Ltd(SZSE:300267) added to Shenzhen Stock Exchange Component A Share Index

Hunan Er-Kang Pharmaceutical Co., Ltd has been added to Shenzhen Stock Exchange Component A Share Index.

Hunan Er-Kang Pharmaceutical Co., Ltd(SZSE:300267) added to Shenzhen Stock Exchange Component Index

Hunan Er-Kang Pharmaceutical Co., Ltd has been added to Shenzhen Stock Exchange Component Index.

Hunan Er-Kang Pharmaceutical Co., Ltd to Propose Amendments to the Articles of Association

Hunan Er-Kang Pharmaceutical Co. Ltd. announced that at the EGM to be held on 13 May 2015, will propose amendments to the articles of association of the company.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
300267:CH CNY31.95 CNY +1.40

300267 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 300267.
View Industry Companies
 

Industry Analysis

300267

Industry Average

Valuation 300267 Industry Range
Price/Earnings 91.5x
Price/Sales 21.8x
Price/Book 17.4x
Price/Cash Flow 90.9x
TEV/Sales 21.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact HUNAN ER-KANG PHARMACEUTI -A, please visit www.hnerkang.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.